Component of red wine may reduce risk of alcohol-related head and neck cancer
the ONA take:
According to a new study in the journal Advances in Experimental Medicine and Biology, researchers at the University of Colorado in Denver, Colorado, have found that resveratrol, a chemical found in grape skins and red wine, may prevent cancer.
Alcohol attacks a person's gene, and for a period of time, the body repairs this damage. When enough alcohol is consume, some DNA damage is no longer repaired, and it is for this reason that alcohol is a risk factor for head and neck cancer. Resveratrol kills these unfixed cells with DNA damage so that they cannot progress to cause cancer.
The body metabolizes alcohol into an intermediate called acetyl aldehyde before converting it to aldehyde dehydrogenase and ultimately acetic acid, which is excreted. Acetyl aldehyde is a known carcinogen.
Hard alcohol increases the risk for head and neck cancer due to the increased level of acetyl aldehyde, but this increased risk is lower among patients who drank red wine, suggesting that there is a component of red wine that inhibits the cancer-causing effect of alcohol.
That component is resveratrol. This substance will not completely reverse the cancer-causing effects of alcohol, but it may reduce the risk for alcohol use to lead to cancer.
Resveratrol, a chemical found in grape skins and red wine, may prevent cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|